Identification of cerebrospinal fluid pharmacodynamic biomarkers and molecular correlates of brain activity in a Phase 2 clinical trial of the Alzheimer's disease drug candidate CT1812

Documenti analoghi

• CSF Phosphoproteomics Biomarker Analysis from the Phase 2 Clinical Trial SHINE to Elucidate the Role of CT1812 in Alzheimer’s Disease
  di: Eunah Cho, et al.
  Pubblicazione: (2024)
• Plasma proteomic analysis of a biomarker‐defined subpopulation in the SHINE Ph2 trial to identify molecular correlates to the favorable decrease in the neuroinflammatory marker GFAP with zervimesine in Alzheimer's disease participants
  di: Britney N Lizama, et al.
  Pubblicazione: (2025)
• Exploratory CSF proteomic analysis of a pre‐specified pTau217 subgroup from the SHINE clinical trial identifies biomarkers correlated with cognitive improvement in Alzheimer’s disease patients treated with zervimesine
  di: Britney N Lizama, et al.
  Pubblicazione: (2025)
• Exploratory CSF proteomics biomarker outcomes of the the phase 2 clinical trial shine to assess the effects of CT1812 in Alzheimer’s patients
  di: Valentina Di Caro, et al.
  Pubblicazione: (2024)
• CT1812 biomarker signature from a meta‐analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease
  di: Britney N. Lizama, et al.
  Pubblicazione: (2024)